EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice

Mohammad Nazmul Hasan, Jianglei Chen, David Matye, Huaiwen Wang, Wenyi Luo, Lijie Gu, Yung Dai Clayton, Yanhong Du, Tiangang Li

Journal of Lipid Research · 2023

DOI: 10.1016/j.jlr.2023.100340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2023. Verfasst von Mohammad Nazmul Hasan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Harold Hamm Diabetes Center, Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Hauptthemen laut MEDLINE: Cholestasis, Liver. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIA NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic reduction of hydrophobic bile acids exposure is considered beneficial in cholestasis. The Cyp2c70 KO mice lack hydrophilic muricholic acids and have a human-like hydrophobic bile acid pool resulting in hepatobiliary injury. This study investigates if combining an apical sodium-dependent bile acid transporter inhibitor GSK2330672 (GSK) and fibroblast growth factor-15 (FGF15) overexpression, via simultaneous inhibition of bile acid synthesis and gut bile acid uptake, achieves enhanced therapeutic efficacy in alleviating hepatobiliary injury in Cyp2c70 KO mice. The effects of GSK, adeno-associated virus (AAV)-FGF15, and the combined treatment on bile acid metabolism and cholangiopathy were compared in Cyp2c70 KO mice. In female Cyp2c70 KO mice with more severe cholangiopathy than male Cyp2c70 KO mice, the combined treatment was more effective in reversing portal inflammation, ductular reaction, and fibrosis than AAV-FGF15, while GSK was largely ineffective. The combined treatment reduced bile acid pool by ∼80% compared to ∼50% reduction by GSK or AAV-FGF15, and enriched tauro-conjugated ursodeoxycholic acid in the bile. Interestingly, the male Cyp2c70 KO mice treated with AAV-FGF15 or GSK showed attenuated cholangiopathy and portal fibrosis but the combined treatment was ineffective despite reducing bile acid pool. Both male and female Cyp2c70 KO mice showed impaired gut barrier integrity. AAV-FGF15 and the combined treatment, but not GSK, reduced gut exposure to lithocholic acid and improved gut barrier function. In conclusion, the combined treatment improved therapeutic efficacy against cholangiopathy than either single treatment in the female but not male Cyp2c70 KO mice by reducing bile acid pool size and hydrophobicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholestasisLiverAnimalsFemaleHumansMiceBile Acids and SaltsFibroblast Growth FactorsFibrosisMice, Inbred C57BLReceptors, Cytoplasmic and NuclearSymportersOrganic Anion Transporters, Sodium-DependentCytochrome P-450 Enzyme System

Stichwörter der Autor:innen

ASBTCYP2C70CYP7A1FXRbile acidcholestasis

Substanzen

Bile Acids and SaltsFibroblast Growth FactorsReceptors, Cytoplasmic and Nuclearsodium-bile acid cotransporterSymportersOrganic Anion Transporters, Sodium-Dependentcytochrome P-450 2C70, mouseCytochrome P-450 Enzyme System

Autor:innen und Institutionen

  • Harold Hamm Diabetes Center, Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Laboratory for Molecular Biology and Cytometry Research, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Harold Hamm Diabetes Center, Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: tiangang-li@ouhsc.edu.

Förderung

  • NIDDK NIH HHS
  • NIA NIH HHS
  • NIH

Zitieren

APA

Hasan, M. N., Chen, J., Matye, D., Wang, H., Luo, W., Gu, L., Clayton, Y. D., Du, Y., & Li, T. (2023). Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2023.100340

Vancouver

Hasan MN, Chen J, Matye D, Wang H, Luo W, Gu L, et al. Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice. Journal of Lipid Research. 2023. doi:10.1016/j.jlr.2023.100340

BibTeX
@article{Hasan2023,
  author = {Hasan, Mohammad Nazmul and Chen, Jianglei and Matye, David and Wang, Huaiwen and Luo, Wenyi and Gu, Lijie and Clayton, Yung Dai and Du, Yanhong and Li, Tiangang},
  title = {Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice},
  journal = {Journal of Lipid Research},
  year = {2023},
  doi = {10.1016/j.jlr.2023.100340}
}
Kostenlos starten →